Virology Quality Control Outlook: Plaque & Hemagglutination Assays for Infectivity Testing
公開 2026/04/02 17:02
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Infectious Particles Titration - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Infectious Particles Titration market, including market size, share, demand, industry development status, and forecasts for the next few years.
For gene therapy developers, vaccine manufacturers, and virology researchers, accurately determining the concentration of infectious viral particles—as opposed to total viral particles that may include non-infectious or defective forms—is critical for dosing, product quality, and biosafety. The global Infectious Particles Titration market addresses this need through quantitative analytical methods that measure functional viral infectivity. As cell and gene therapies advance toward commercialization and viral vector manufacturing scales, demand for robust infectious particle titration continues to grow.
The global market for Infectious Particles Titration was estimated to be worth US$ 6509 million in 2025 and is projected to reach US$ 14170 million, growing at a CAGR of 11.9% from 2026 to 2032. This robust growth reflects expanding viral vector-based therapies and increasing regulatory requirements for infectivity testing.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097145/infectious-particles-titration
Functional Viral Concentration for Biologics Quality Control
Infectious particles titration refers to a set of quantitative analytical methods used to determine the concentration of infectious viral particles (as opposed to total viral particles, which may include non-infectious or defective forms) in a sample. It is a critical procedure in virology, vaccine development, gene therapy, and biologics manufacturing, ensuring accurate dosing, product quality, and biosafety.
Unlike physical titration methods (e.g., qPCR, ELISA) that measure total viral particles (including empty capsids and non-infectious forms), infectious titration measures only functional, replication-competent viruses. This distinction is critical for gene therapy products, where non-infectious particles dilute potency, and for vaccine manufacturing, where infectivity correlates with immunogenicity.
Industry Segmentation: Testing Methods & Applications
The Infectious Particles Titration market is segmented by analytical approach and end-use application:
Plaque Test (Plaque Assay): The gold standard for infectious titration, measuring viral infectivity by counting plaque-forming units (PFU) on susceptible cell monolayers. A major gene therapy manufacturer recently implemented automated plaque imaging for AAV infectious titer determination, improving throughput and consistency.
Hemagglutination Test: Measures viral particles that agglutinate red blood cells (e.g., influenza virus). While faster than plaque assays, hemagglutination titers correlate with total viral particles rather than strictly infectious particles.
Others: TCID50 (50% tissue culture infectious dose), focus-forming assays, and flow cytometry-based infectivity assays. Emerging methods include digital PCR-based infectivity assays and high-content imaging.
Application Segments
Cell and Gene Therapy: Viral vector (AAV, lentivirus, retrovirus) infectious titer determination for product release and process development. A leading AAV gene therapy company reported that infectious titer correlation with in vivo potency was essential for regulatory approval.
Vaccine Development and Production: Live-attenuated and inactivated viral vaccines require infectious titer testing for lot release and stability monitoring.
Virology Research: Academic and pharmaceutical research laboratories use infectious titration for viral pathogenesis studies, antiviral drug screening, and basic virology.
Others: Oncolytic virus development and diagnostic virology.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Automated plaque imaging and counting systems have reduced manual variability and improved throughput for high-volume testing. High-content imaging-based infectivity assays enable multiplexed detection of multiple viral types. Digital PCR-based infectivity assays are emerging as rapid alternatives to traditional cell-based methods.
The trend toward process analytical technology (PAT) for viral vector manufacturing is driving development of rapid, in-process infectious titer methods. Regulatory expectations for infectious titer characterization of gene therapy products have increased, requiring orthogonal methods for comprehensive product understanding. Outsourcing of infectious titration to specialized CROs continues as smaller gene therapy companies lack in-house virology capabilities.
Regional Market Dynamics
North America leads the infectious particles titration market, driven by the largest concentration of gene therapy companies, robust FDA regulatory framework, and strong CRO infrastructure. The United States dominates with significant viral vector manufacturing capacity.
Europe follows closely, with strong gene therapy development in the UK, Germany, and Switzerland, and EMA regulatory requirements driving testing demand. Asia-Pacific is the fastest-growing region, with expanding gene therapy pipelines, increasing vaccine manufacturing, and growing CRO capabilities in China, Japan, South Korea, and Singapore.
Competitive Landscape
Key players include Thermo Fisher Scientific, Charles River Laboratories, Catalent, Lonza, GenScript, Viroclinics, Virapur, Vigene Biosciences, Creative Biolabs, Avance Biosciences, and Takara Bio.
Market Segmentation
The Infectious Particles Titration market is segmented as below:
By Company
Thermo Fisher Scientific
Charles River Laboratories
Catalent
Lonza
GenScript
Viroclinics
Virapur
Vigene Biosciences
Creative Biolabs
Avance Biosciences
Takara Bio
Segment by Type
Plaque Test
Hemagglutination Test
Others
Segment by Application
Cell and Gene Therapy
Vaccine Development and Production
Virology Research
Others
Exclusive Industry Outlook
Looking ahead, the convergence of infectious particles titration technology with automation, rapid analytics, and cell and gene therapy manufacturing represents a significant growth frontier. Real-time infectious titer monitoring using optical or impedance-based sensors will enable continuous manufacturing. Development of cell-free infectivity assays (using digital PCR or sequencing) will reduce assay timelines from days to hours. Integration of infectious titration with potency assays will streamline product release testing. Additionally, the trend toward allogeneic cell therapies will increase demand for viral vector infectivity testing for engineering steps. The ability to offer infectious particles titration that combines regulatory expertise, analytical rigor, and rapid turnaround—supported by global laboratory networks—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For gene therapy developers, vaccine manufacturers, and virology researchers, accurately determining the concentration of infectious viral particles—as opposed to total viral particles that may include non-infectious or defective forms—is critical for dosing, product quality, and biosafety. The global Infectious Particles Titration market addresses this need through quantitative analytical methods that measure functional viral infectivity. As cell and gene therapies advance toward commercialization and viral vector manufacturing scales, demand for robust infectious particle titration continues to grow.
The global market for Infectious Particles Titration was estimated to be worth US$ 6509 million in 2025 and is projected to reach US$ 14170 million, growing at a CAGR of 11.9% from 2026 to 2032. This robust growth reflects expanding viral vector-based therapies and increasing regulatory requirements for infectivity testing.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097145/infectious-particles-titration
Functional Viral Concentration for Biologics Quality Control
Infectious particles titration refers to a set of quantitative analytical methods used to determine the concentration of infectious viral particles (as opposed to total viral particles, which may include non-infectious or defective forms) in a sample. It is a critical procedure in virology, vaccine development, gene therapy, and biologics manufacturing, ensuring accurate dosing, product quality, and biosafety.
Unlike physical titration methods (e.g., qPCR, ELISA) that measure total viral particles (including empty capsids and non-infectious forms), infectious titration measures only functional, replication-competent viruses. This distinction is critical for gene therapy products, where non-infectious particles dilute potency, and for vaccine manufacturing, where infectivity correlates with immunogenicity.
Industry Segmentation: Testing Methods & Applications
The Infectious Particles Titration market is segmented by analytical approach and end-use application:
Plaque Test (Plaque Assay): The gold standard for infectious titration, measuring viral infectivity by counting plaque-forming units (PFU) on susceptible cell monolayers. A major gene therapy manufacturer recently implemented automated plaque imaging for AAV infectious titer determination, improving throughput and consistency.
Hemagglutination Test: Measures viral particles that agglutinate red blood cells (e.g., influenza virus). While faster than plaque assays, hemagglutination titers correlate with total viral particles rather than strictly infectious particles.
Others: TCID50 (50% tissue culture infectious dose), focus-forming assays, and flow cytometry-based infectivity assays. Emerging methods include digital PCR-based infectivity assays and high-content imaging.
Application Segments
Cell and Gene Therapy: Viral vector (AAV, lentivirus, retrovirus) infectious titer determination for product release and process development. A leading AAV gene therapy company reported that infectious titer correlation with in vivo potency was essential for regulatory approval.
Vaccine Development and Production: Live-attenuated and inactivated viral vaccines require infectious titer testing for lot release and stability monitoring.
Virology Research: Academic and pharmaceutical research laboratories use infectious titration for viral pathogenesis studies, antiviral drug screening, and basic virology.
Others: Oncolytic virus development and diagnostic virology.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Automated plaque imaging and counting systems have reduced manual variability and improved throughput for high-volume testing. High-content imaging-based infectivity assays enable multiplexed detection of multiple viral types. Digital PCR-based infectivity assays are emerging as rapid alternatives to traditional cell-based methods.
The trend toward process analytical technology (PAT) for viral vector manufacturing is driving development of rapid, in-process infectious titer methods. Regulatory expectations for infectious titer characterization of gene therapy products have increased, requiring orthogonal methods for comprehensive product understanding. Outsourcing of infectious titration to specialized CROs continues as smaller gene therapy companies lack in-house virology capabilities.
Regional Market Dynamics
North America leads the infectious particles titration market, driven by the largest concentration of gene therapy companies, robust FDA regulatory framework, and strong CRO infrastructure. The United States dominates with significant viral vector manufacturing capacity.
Europe follows closely, with strong gene therapy development in the UK, Germany, and Switzerland, and EMA regulatory requirements driving testing demand. Asia-Pacific is the fastest-growing region, with expanding gene therapy pipelines, increasing vaccine manufacturing, and growing CRO capabilities in China, Japan, South Korea, and Singapore.
Competitive Landscape
Key players include Thermo Fisher Scientific, Charles River Laboratories, Catalent, Lonza, GenScript, Viroclinics, Virapur, Vigene Biosciences, Creative Biolabs, Avance Biosciences, and Takara Bio.
Market Segmentation
The Infectious Particles Titration market is segmented as below:
By Company
Thermo Fisher Scientific
Charles River Laboratories
Catalent
Lonza
GenScript
Viroclinics
Virapur
Vigene Biosciences
Creative Biolabs
Avance Biosciences
Takara Bio
Segment by Type
Plaque Test
Hemagglutination Test
Others
Segment by Application
Cell and Gene Therapy
Vaccine Development and Production
Virology Research
Others
Exclusive Industry Outlook
Looking ahead, the convergence of infectious particles titration technology with automation, rapid analytics, and cell and gene therapy manufacturing represents a significant growth frontier. Real-time infectious titer monitoring using optical or impedance-based sensors will enable continuous manufacturing. Development of cell-free infectivity assays (using digital PCR or sequencing) will reduce assay timelines from days to hours. Integration of infectious titration with potency assays will streamline product release testing. Additionally, the trend toward allogeneic cell therapies will increase demand for viral vector infectivity testing for engineering steps. The ability to offer infectious particles titration that combines regulatory expertise, analytical rigor, and rapid turnaround—supported by global laboratory networks—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ